Stockscreener 앱 받기
7.70
1.85%
0.14
시장 영업 전:
7.67
-0.03
-0.39%
전일 마감가:
$7.56
열려 있는:
$7.55
하루 거래량:
1.54M
Relative Volume:
1.17
시가총액:
$691.29M
수익:
$823.60M
순이익/손실:
$-116.00M
주가수익비율:
-5.9231
EPS:
-1.3
순현금흐름:
$-107.30M
1주 성능:
+2.67%
1개월 성능:
-5.29%
6개월 성능:
-56.27%
1년 성능:
-60.45%
1일 변동 폭
$7.36
$7.78
1주일 범위
$6.94
$7.78
52주 변동 폭
$6.94
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.70 | 691.29M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
422.27 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.40 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
475.07 | 34.90B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
108.37 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.30 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 개시 | Craig Hallum | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
PARP Inhibitor Biomarkers Market Top PlayersMyriad Genetics, - openPR.com
Myriad Genetics Quarterly Earnings Preview: What to ExpectNews and Statistics - IndexBox
What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings - Yahoo Finance
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help - Hometown Stations
Press Release Distribution & PR Platform - ACCESS Newswire
Molecular Diagnostics Market to Witness Remarkable Growth with - openPR.com
Myriad Genetics: Significantly Undervalued With Profitability In Sight - Seeking Alpha
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight - GlobeNewswire Inc.
Myriad Genetics (MYGN) Survey Highlights Views on Mental Health Medication | MYGN Stock News - GuruFocus
Concerns about Mental Health Medication Side Effects Remain - GlobeNewswire
Mental Health Breakthrough: New Genetic Test Could End Medication Trial-and-Error, Study Shows - Stock Titan
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 - GlobeNewswire
Myriad Genetics Announces Triple Investor Event: Q1 Earnings Plus Two Elite Healthcare Conferences - Stock Titan
10-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad Genetics Highlights MRD Clinical Validity Data at America - GuruFocus
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting - The Manila Times
Breakthrough Cancer Detection Test Achieves 94% Survival Rate, Doubles Treatment Window in Kidney Cancer Study - Stock Titan
3 Healthcare Stocks That Concern Us - Yahoo Finance
Myriad Genetics Unveils Promising Clinical Data on Precise MRD Test for Oligometastatic Clear-Cell Renal Cell Carcinoma at AACR Annual Meeting - Nasdaq
Myriad Genetics stock hits 52-week low at $7.28 amid sharp decline - Investing.com India
Myriad Genetics stock hits 52-week low at $7.28 amid sharp decline By Investing.com - Investing.com South Africa
Microtomes Market Projected To Witness Substantial Growth, - openPR.com
Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with - GuruFocus
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? - Yahoo Finance
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing | MYGN Stock News - GuruFocus
Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with GeneSight Test | MYGN Stock News - GuruFocus
Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients - Nasdaq
Myriad Genetics Announces Study Results Show Patients with - GlobeNewswire
New Study: Depression Patients See 40% Drop in Drug Complications with GeneSight Genetic Test - Stock Titan
Demystifying Myriad Genetics: Insights From 10 Analyst Reviews - Benzinga
Pancreatic Cancer Market Growth, Trends & Forecast 2024-2031 | - openPR.com
Myriad Genetics price target lowered to $9 from $11 at BofA - Yahoo Finance
Myriad Genetics (MYGN) Sees Price Target Lowered by BofA Amid Po - GuruFocus
8-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Genetic Screening Testing for Preventive Health Market Top - openPR.com
Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN
Guggenheim Downgrades Myriad Genetics to Neutral From Buy - marketscreener.com
Myriad Genetics Announces Inducement Awards - The Manila Times
Myriad Genetics Announces Inducement Awards | MYGN Stock News - GuruFocus
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
0.46%
자본화:
|
볼륨(24시간):